Xu, William

Abstract Background Failure to rescue (FTR) is a key driver of postoperative mortality and reflects a hospital’s ability to recognize, escalate, and treat complications. Although FTR varies substantially between hospitals, the hospital characteristics that underpin this variation are inconsistently described. The aim of this study was to synthesize evidence on hospital-level factors associated with FTR after postoperative complications across surgical populations and health systems. Methods A systematic review of observational studies evaluating associations between hospital-level characteristics and FTR in surgical patients was undertaken. MEDLINE, EMBASE, and Scopus were systematically searched on 17 July 2024 and updated to 31 December 2025. Hospital factors were classified into structural, staffing, and system domains. Where three or more non-overlapping studies reported adjusted estimates in comparable formats, random-effects meta-analyses were performed; otherwise, findings were summarized narratively. Methodological quality of included studies was assessed using the ROBINS-I tool (version 2). Results A total of 111 studies encompassing over 137 million patients and 301 hospital factors were included. Meta-analyses demonstrated lower FTR rates in larger hospitals (odds ratio 0.85, 95% confidence interval 0.74 to 0.97), hospitals with greater intensive care unit capacity (odds ratio 0.80, 0.71 to 0.90), and teaching hospitals (odds ratio 0.88, 0.83 to 0.93). Better nursing resources were consistently associated with lower FTR, including patient-to-nurse ratios (odds ratio 1.07, 1.03 to 1.10), higher nurse education (odds ratio 0.95, 0.91 to 0.99), and more favourable work environments (odds ratio 0.93, 0.90 to 0.95). Safety-net hospital status was associated with higher FTR (odds ratio 1.22, 1.03 to 1.45). Substantial heterogeneity was observed across most analyses. Conclusion Hospital-level structural, staffing, and system characteristics are associated with variation in FTR. Postoperative mortality is closely linked to institutional capacity to detect and manage complications, underscoring the importance of adequate resourcing and system organization to improve surgical outcomes.

ABSTRACT Introduction Chronic gastroduodenal disorders remain challenging to manage, and new diagnostic approaches are needed to better delineate underlying causes and guide therapeutic decisions. Body Surface Gastric Mapping (BSGM) technologies combine high‐resolution gastric myoelectrical activity measurements with symptom and psychological profiling to provide mechanistic insights into gastric motor and sensory dysfunction. An International Working Group convened to derive the first consensus classification of BSGM phenotypes (the “Auckland Classification”). Methods A Technical Group conducted a systematic literature and clinical database review to identify objective test biomarkers and candidate disease mechanisms. Evidence was synthesized across 50 studies (primarily in gastroparesis, chronic nausea and vomiting, and functional dyspepsia), and BSGM phenotypes were mapped to existing treatment guidelines. Subsequently, iterative review and development of consensus was performed by a Consensus Group composed of international clinical experts familiar with BSGM. Eleven statements underlying the classification were then derived and circulated as a final survey to establish agreement. Results Six BSGM phenotypes were endorsed: three defined by myoelectrical abnormalities (Dysrhythmic, High Frequency, and Low Meal Response) and three by characteristic symptom associations (Sensorimotor, Continuous, and Delayed Onset Symptoms). Published studies plausibly linked these phenotypes to mechanisms including interstitial cell of Cajal depletion, vagal impairment, hypomotility, visceral hypersensitivity, gut‐brain dysregulation, and small bowel dysfunction. Phenotypes were also mapped to existing mechanism‐based treatment guidelines. Ten out of the eleven statements had > 80% agreement. Conclusions The Auckland Classification, derived by international consensus, presents a structured framework for BSGM‐defined patient phenotypes. Evidence and mechanism‐based treatment options are suggested for each phenotype to provide a foundation for research, further validation, and a pathway for integrating BSGM into clinical care.